论文部分内容阅读
目的探讨p130Cas在卵巢上皮性癌中的表达及意义。方法应用免疫组化方法检测p130Cas在80例卵巢上皮性癌和30例正常卵巢组织中的表达,并分析其表达与肿瘤临床病理因素及预后的相关性。结果 p130Cas在卵巢上皮性癌中的阳性表达率高于其在正常卵巢组织中的表达(73.75%vs.10.00%,P<0.001);在卵巢上皮性癌中,FIGOⅢ期患者p130Cas阳性表达率高于FIGO分期Ⅰ+Ⅱ患者(84.6%vs.56.8%,P=0.005);p130Cas高表达的患者有更差的卵巢癌特异性5年累计生存率(P=0.002),经多因素分析有统计学意义(P=0.036)。结论 p130Cas高表达可能促进卵巢上皮性癌的发生,并与其更晚的分期和不良预后相关。
Objective To investigate the expression and significance of p130Cas in epithelial ovarian cancer. Methods The expression of p130Cas was detected by immunohistochemistry in 80 cases of ovarian epithelial carcinoma and 30 cases of normal ovarian tissue. The correlation between the expression of p130Cas and clinical, pathological factors and prognosis was analyzed. Results The positive rate of p130Cas expression in ovarian epithelial carcinoma was higher than that in normal ovarian tissue (73.75% vs.10.00%, P <0.001). In ovarian epithelial carcinoma, the positive rate of p130Cas in FIGOⅢpatients was high In the patients with FIGO stage Ⅰ + Ⅱ (84.6% vs.56.8%, P = 0.005), patients with high expression of p130Cas had poorer ovarian cancer specific 5-year cumulative survival rate (P = 0.002) Significance of learning (P = 0.036). Conclusion The high expression of p130Cas may promote the occurrence of epithelial ovarian cancer and is associated with its later stage and poor prognosis.